Abstract 111P
Background
Immunohistochemistry (IHC)/in situ hybridization (ISH) are widely used methods in many pathology laboratories to assess human epidermal growth factor receptor 2 (HER2) status in gastric cancer (GC) patients. Nowadays, next generation sequencing (NGS) technologies are adopted to precisely predict absolute gene amplification levels. However, these tissue-based tests are suffering from intratumoral heterogeneity and inter-laboratory technical biases.
Methods
We set up a novel probe-based Absolute Q digital PCR assays for quantitative measurement of HER2 amplification using the formalin-fixed paraffin embedded (FFPE) tissue samples and the results were compared with IHC/ISH and NGS results in 184 gastric adenocarcinoma samples. HER2 amplifications were determined with HER2 TaqMan® probe hydrolysis assays within exon 22 and was multiplexed by the ratios of HER2 copy number (CN) to reference gene CN (HER2/RNaseP ratio).
Results
With digital PCR, the median HER2 CN were 1.79 copies/μL (ranged from 0.02 to 48.87 copies/μL). With NGS, HER2 amplifications were detected in 28 cases (15.2%). By IHC, HER2 positive (3+) was found in 25 cases (13.6%) and equivocal (2+) cases were observed in 15 cases (8.2%), in which ISH conformed amplifications in 13 cases. The concordance rate between IHC (3+ or 2+ and HER2 amplified) and NGS was 71.3%. In HER2-amplified cases by NGS, the median CN measured with digital PCR were 9.7 copies/μL (ranged from 1.95 to 48.87 copies/μL). In statistical analyses, Pearson correlation coefficients between NGS and digital PCR was 0.916, suggesting strong correlation. Given HER2 amplification by NGS as the standard reference, digital PCR predicted HER2 amplification with a 98.7% specificity, 92.9% sensitivity, 92.9% positive predictive value, and 98.7% negative predictive value. The AUC values for predicting HER2 amplification by digital PCR were 0.989.
Conclusions
With newly designed novel probes, digital PCR accurately measured HER2 CN with high sensitivity and specificity.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Ministry of Health & Welfare, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract